O‘PKA SARATONINING KLINIK-MORFOLOGIK XUSUSIYATLARI HAMDA CD34, P53 VA PD-L1 IMMUNOGISTOKIMYOVIY KO‘RSATKICHLARINING TAVSIFIY TAHLILI
DOI:
https://doi.org/10.5281/zenodo.23734388Keywords:
o‘pka saratoni, mayda hujayrali bo‘lmagan o‘pka saratoni, gistologik turlar, CD34, p53, PD-L1, immunogistokimyo, qon tomir endoteliysi, klinik bosqichAbstract
Tadqiqotning maqsadi ikki hududiy onkologiya markazida o‘pka saratoni bilan kasallangan bemorlarning klinik-morfologik xususiyatlarini tavsiflash hamda tanlangan mayda hujayrali bo‘lmagan o‘pka saratoni namunalarida CD34, p53 va PD-L1 immunogistokimyoviy ko‘rsatkichlarini baholashdan iborat. 2020–2025-yillarda Respublika ixtisoslashtirilgan onkologiya va radiologiya ilmiy-amaliy tibbiyot markazining Navoiy (n=200) va Toshkent (n=100) viloyat filiallarida qayd etilgan 300 nafar bemorning klinik-arxiv ma’lumotlari retrospektiv tavsifiy tahlil qilindi. Navoiy filialidan tanlangan 60 nafar bemorning IGX natijalari ko‘rib chiqildi: arxiv tashxislariga ko‘ra, yassi hujayrali saraton, adenokarsinoma va yirik hujayrali saraton guruhlarining har biriga 20 nafardan bemor kiritilgan. Erkaklar 245/300 (81,7%), 60–74 yoshdagilar esa 162/300 (54,0%) ni tashkil etdi. III–IV bosqich 274/300 bemorda (91,3%; 95% ishonch oralig‘i: 87,6–94,0%) qayd etildi. Barcha 60 ta to‘qima namunasida CD34-musbat qon tomir endoteliysi aniqlandi. Adenokarsinomada >60% ekspressiya toifasi p53 bo‘yicha 10/20 (50,0%), PD-L1 bo‘yicha esa 9/20 (45,0%) holatda kuzatildi. Markerlar ekspressiyasi tanlangan gistologik guruhlarda tavsifiy jihatdan farqlandi.References
1. Bray, F., Laversanne, M., Sung, H., et al. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 74(3), 229–263. https://doi.org/10.3322/
2. Nicholson, A. G., Tsao, M. S., Beasley, M. B., et al. (2022). The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. J Thorac Oncol, 17(3), 362–387. https://doi.org/10.1016/j.jtho.2021.11.003
3. Sholl, L. M., & Awad, M. (2024). Basu Roy U, et al. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline. Arch Pathol Lab Med, 148(7), 757–774. https://doi.org/10.5858/arpa.2023-0536-CP
4. Niklinska, W., Burzykowski, T., Laudanski, J., Chyczewska, E., Chyczewski, L., & Niklinski, J. (2001). Strong association between P53 protein accumulation, serum antibodies and gene mutation in non-small cell lung cancer. Folia Histochem Cytobiol, 39(2), 51–56.
5. Offersen, B. V., Pfeiffer, P., Hamilton-Dutoit, S., & Overgaard, J. (2001). Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer, 91(8), 1500–1509.
6. von Elm, E., Altman, D. G., Egger, M., et al. (2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. doi:10.1371/journal.pmed.0040296. https://doi.org/10.1371/journal.pmed.0040296
7. Agilent Technologies. PD-L1 IHC 22C3 pharmDx: Instructions for Use. Document P03951_28.00/SK00621-5. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150013S032D.pdf. (Cited as a scoring methodology reference; use of this assay in the current cohort was not verified.)
8. Pezzella, F., Pastorino, U., Tagliabue, E., et al. (1997). Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol, 151(5), 1417–1423.

